Antiplatelet agents in complex medication therapy in diabetic foot disease
K.A. Koreyba
Abstract
The urgency of the problem concerning treatment of diabetic foot disease is due to the following reasons: pathogenesis ambiguity of this pathology, tendency to trophic defects relapse and increase in volume during the conservative treatment, resistance to conservative treatment, deterioration of the life quality of patients, treatment complexity and duration, and significant economic costs for treatment and rehabilitation. The patterns of complex medication therapy effects include insufficient evidence for most drugs, the lack of generally accepted regimens and the low efficacy of existing ones. Given the own experience and using a mathematical model, it was proved that the benefits of using Cilostazol as part of combined medication therapy regimen for patients with diabetic foot syndrome and stage IIA, IIB chronic limb ischemia according to the classification of Fontaine-Leriche-Pokrovsky. The need to adhere to National Clinical Guidelines was justified.KEYWORDS: diabetic foot syndrome, national clinical guidelines, disaggregants, pulse oximetry, chronic limb ischemia, oxygen saturation,outcomes assessment.FOR CITATION: Koreyba K.A. Antiplatelet agents in complex medication therapy in diabetic foot disease. Russian Medical Inquiry. 2020;4(7):457–462. DOI: 10.32364/2587-6821-2020-4-7-457-462.